Skip to main content

SINUS SURGERY + SCS USE IN ADULTS

HELP BREAK THE CYCLE OF REPEAT SURGERY AND
SYSTEMIC STEROID TREATMENT WITH DUPIXENT1,2

HELP BREAK THE CYCLE OF REPEAT SURGERY AND
SYSTEMIC STEROID TREATMENT WITH DUPIXENT1,2

In SINUS trials, 63% of patients had prior surgery1,2

83%

REDUCTION IN THE
NEED
FOR SINUS
SURGERY

vs placebo through Week 52 (HR: 0.17 [95% CI: 0.07, 0.46])1

74%

REDUCTION IN THE
NEED FOR SYSTEMIC
STEROID USE

vs placebo through Week 52 (HR: 0.26 [95% CI: 0.18, 0.38])1

There was a 76% reduction in the need for surgery and/or systemic steroids vs placebo through Week 52
(HR: 0.24 [95% Cl: 0.17, 0.35]).1,a,b

aIndividually, systemic steroid use reduction and need for sinus surgery were not multiplicity-adjusted endpoints.1,2

bIn SINUS-24 and SINUS-52, DUPIXENT 300 mg Q2W + INCS (Day 0: n=438; Week 24: n=376; Week 52: n=100); placebo + INCS (Day 0: n=286; Week 24: n=187; Week 52: n=61).1

HR, hazard ratio; INCS, intranasal corticosteroid; Q2W, once every 2 weeks.

Use of DUPIXENT for the CRSwNP indication in patients aged 12-17 years is supported by evidence from studies of DUPIXENT as add-on maintenance
treatment in adults with inadequately controlled CRSwNP.1

SEE NASAL POLYP
SCORE RESULTS

BACK TO NASAL
CONGESTION RESULTS

Explore the Safety Data and Study Designs

View Safety Data SEE THE FULL STUDY DESIGNS

Dosage and
Administration

See the recommended dosing and
administration options for patients
on DUPIXENT.

Explore ADMINISTRATION Options